$KPRX News

Kiora Pharmaceuticals Files Prospectus For Offering 11.797M Common Stock On Behalf Of Selling Shareholders

Kiora Pharmaceuticals Q1 EPS $(0.58) Beats $(0.71) Estimate

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

Kiora Pharmaceuticals shares are trading higher after the company announced it will sell up to 438,471 shares in a private placement.

Kiora Pharmaceuticals shares are trading higher after the company announced it will sell up to 438,471 shares in a private placement.

Kiora Pharmaceuticals Entered Securities Purchase Agreement On April 3, 2026; To Issue 438,471 Shares Of Common Stock In Private Placement

Kiora Pharmaceuticals Announces Management Team Changes

Kiora Pharmaceuticals Q4 EPS $(1.60) Misses $(0.67) Estimate

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Kiora Pharmaceuticals Secures New US Patent to Expand Delivery Options for Eye Drug KIO-104

Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases

Kiora Pharmaceuticals Q3 EPS $0.01 May Not Be Comparable To $(0.66) Estimate

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Kiora Pharmaceuticals Joins Global Genes' RARE-X Vision Consortium, A Corporate-Nonprofit Initiative Aimed At Advancing Research For Rare Ocular Disorders

Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025